Medicare Enrolled

Dr. Namieta Janssen, M.D.

Rheumatology · Sugar Land, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Speaking/Promotional
1327 LAKE POINTE PKWY STE 325, Sugar Land, TX 77478
8325005002
In practice since 2006 (19 years)
NPI: 1609979947 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Janssen from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Janssen? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Janssen

Dr. Namieta Janssen is a rheumatology in Sugar Land, TX, with 19 years in practice. Based on federal Medicare data, Dr. Janssen performed 193,838 Medicare services across 664 unique beneficiaries.

Between the years covered by Open Payments, Dr. Janssen received a total of $430,247 from 37 pharmaceutical and/or device companies across 1298 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Janssen is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ Top 5% volume in TX$ $430,247 industry payments

Medicare Practice Summary

Medicare Utilization ↗
193,838
Medicare services
Top 5% in TX for rheumatology
664
Unique beneficiaries
$6
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~10,202 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Certolizumab injection (Cimzia)178,000$4$15
Abatacept infusion (Orencia)12,200$34$75
Denosumab injection (Prolia/Xgeva)1,380$18$35
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle890$55$255
Administration of chemotherapy into vein, 1 hour or less291$98$350
Blood draw (venipuncture)255$7$7
Office visit, established patient (30-39 min)253$90$155
Administration of chemotherapy into vein, each additional hour118$21$100
Injection of additional new drug or substance into vein104$12$55
Office visit, established patient (20-29 min)104$63$125
Injection, zoledronic acid, 1 mg85$6$100
Drug injection, under skin or into muscle77$11$40
Flu vaccine, high-dose32$72$110
Flu vaccine administration32$30$50
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less17$45$155
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
6.3% high complexity
93.3% medium
0.3% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$430,247
Total received (2018-2024)
Avg $61,464/year across 7 years
Top 2% in TX for rheumatology
37
Companies
1,298
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$405,002 (94.1%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$14,132 (3.3%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$11,113 (2.6%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$4,508
2023
$92,857
2022
$71,361
2021
$60,001
2020
$35,193
2019
$104,078
2018
$62,249

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
UCB, Inc.
$181,624
GlaxoSmithKline, LLC.
$171,082
Lilly USA, LLC
$41,301
GENZYME CORPORATION
$6,654
Aurinia Pharma U.S., Inc.
$6,047
AstraZeneca Pharmaceuticals LP
$5,100
Regeneron Healthcare Solutions, Inc.
$4,362
Amgen Inc.
$2,749
Janssen Biotech, Inc.
$2,565
Novartis Pharmaceuticals Corporation
$1,509
PFIZER INC.
$1,088
ABBVIE INC.
$1,027
AbbVie, Inc.
$899
E.R. Squibb & Sons, L.L.C.
$802
AbbVie Inc.
$594
Genentech USA, Inc.
$482
Celgene Corporation
$446
Radius Health, Inc.
$347
Mallinckrodt Enterprises LLC
$308
Johnson & Johnson Health Care Systems Inc.
$279
Antares Pharma, Inc.
$128
Horizon Therapeutics plc
$126
Horizon Pharma plc
$121
Mallinckrodt Hospital Products Inc.
$105
SANOFI-AVENTIS U.S. LLC
$84
Sobi, Inc
$80
Organon LLC
$72
Merck Sharp & Dohme Corporation
$61
MEDEXUS PHARMA, INC.
$60
Boehringer Ingelheim Pharmaceuticals, Inc.
$33
Alexion Pharmaceuticals, Inc.
$28
Teva Pharmaceuticals USA, Inc.
$18
Takeda Pharmaceuticals U.S.A., Inc.
$18
Ultragenyx Pharmaceutical Inc.
$16
Oxford Immunotec USA Inc
$13
MEDAC PHARMA, INC.
$11
Organon Llc
$5
Top 3 companies account for 91.6% of total payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · AVSOLA · Actemra · BENLYSTA · Bimzelx · CHANTIX · COSENTYX · Cimzia · Crysvita · DUEXIS · EVENITY · EVUSHELD · Enbrel · FORTEO · HADLIMA · HUMIRA · Humira · INFLECTRA · KEVZARA · KEVZARA SARILUMAB INJECTION · KRYSTEXXA · Kineret · LUPKYNIS · NEXPLANON · NUCALA · OFEV · ORENCIA · OTREXUP · Otezla · Otrexup · PENNSAID · PREVNAR 20 · Prolia · RAYOS · REMICADE · RENFLEXIS · RHEUMATOID ARTHRITIS DISEASE · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · TALTZ · TAVNEOS · TREMFYA · TSPOT TB TEST · Truxima · Tymlos · Uloric · XELJANZ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (94%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in rheumatology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 2% for rheumatology in TX.

Equivalent to $222 per 100 Medicare services performed
Looking for a rheumatology in Sugar Land?
Compare rheumatologys in the Sugar Land area by procedure volume, costs, and industry payment transparency.
Browse rheumatologys nearby

Geographic Context

Rheumatologys within 10 mi
66
Per 100K population
7.7
County median income
$113,409
Nearest hospital
ST LUKE'S SUGAR LAND HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Janssen is a mixed practice specialist, with above-average Medicare volume (top 5% in TX), and high industry engagement (speaking/promotional, top 2%), with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Janssen experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Janssen performed 178,000 certolizumab injection (cimzia) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Janssen receive payments from pharmaceutical companies?
Yes. Dr. Janssen received a total of $430,247 from 37 companies across 1,298 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Janssen's costs compare to other rheumatologys in Sugar Land?
Dr. Janssen's average Medicare payment per service is $6. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Janssen) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →